Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

LSD1 inhibition attenuates targeted therapy-induced lineage plasticity in BRAF mutant colorectal cancer

22 Apr 2025

Abstract excerpt

Abstract Background BRAF activating mutations occur in approximately 10% of metastatic colorectal cancer (CRCs) and are associated with worse prognosis in part due to an inferior response to standard chemotherapy. Standard of care for patients with refractory metastatic BRAF V600E CRC is treatment with BRAF and EGFR inhibitors and recent FDA approval was given to use these inhibitors in combination with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Cancer Cells and Metastasis
Share to Fibroblast Growth Factor Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40264166
DOI: 10.1186/s12943-025-02311-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

LSD1 inhibition attenuates targeted therapy-induced lineage plasticity in BRAF mutant colorectal cancerPMID 40264166Read ↗

LSD1 inhibition attenuates targeted therapy-induced lineage plasticity in <i> BRAF <sup>V600E</sup> </i> colorectal cancerSemantic proximity Read ↗

LSD1 promotes secretory cell specification to drive <i>BRAF</i> mutant colorectal cancerSemantic proximity Read ↗

LSD1 and Aberrant DNA Methylation Mediate Persistence of Enteroendocrine Progenitors That Support BRAF -Mutant Colorectal CancerSemantic proximity Read ↗

Adaptive Plasticity Tumor Cells Modulate MAPK-Targeting Therapy Response in Colorectal CancerSemantic proximity Read ↗

Reprogramming of Cellular Plasticity via ETS and MYC Core-regulatory Circuits During Response to MAPK Inhibition in BRAF-mutant Colorectal CancerSemantic proximity Read ↗

Histone demethylase LSD1 controls the phenotypic plasticity of cancer cells.Semantic proximity Read ↗

Intrinsic and Acquired Drug Resistance to LSD1 Inhibitors in SCLC Occurs through a TEAD4 Driven Transcriptional StateSemantic proximity Read ↗

MAPK-driven epithelial cell plasticity drives colorectal cancer therapeutic resistance.Semantic proximity Read ↗

BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.Semantic proximity Read ↗

Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas.Semantic proximity Read ↗

Reprogramming of Cellular Plasticity via ETS and MYC Core-Regulatory Circuits during Response to MAPK Inhibition in BRAF-Mutant Colorectal Cancer.Semantic proximity Read ↗

Lsd1 as a therapeutic target in Gfi1-activated medulloblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.